PURPOSE: The majority of patients with non-small cell lung cancer (NSCLC) present at an advanced clinical stage, when surgery is not a recommended therapeutic option. In such cases, tissues for molecular research are usually limited to the low-volume samples obtained at the time of diagnosis, usually via fine-needle aspiration (FNA). We tested the feasibility of performing gene expression profiling of advanced NSCLCs using amplified RNA from lung FNAs. EXPERIMENTAL DESIGN AND RESULTS: A total of 46 FNAs was tested, of which 18 yielded RNA of sufficient quality for microarray analysis. Expression profiles of these 18 samples were compared with profiles of 17 pairs of tumor and normal lung tissues that had been surgically obtained. Using a variety of unsupervised and supervised analytical approaches, we found that the FNA profiles were highly distinct from the normal samples and similar to the tumor profiles. CONCLUSIONS: We conclude that when RNA amplification is successful, gene expression profiles from NSCLC FNAs can determine malignancy and suggest that with additional refinement and standardization of sample collection and RNA amplification protocols, it will be possible to conduct additional and more detailed molecular analysis of advanced NSCLC using lung FNAs.
PURPOSE: The majority of patients with non-small cell lung cancer (NSCLC) present at an advanced clinical stage, when surgery is not a recommended therapeutic option. In such cases, tissues for molecular research are usually limited to the low-volume samples obtained at the time of diagnosis, usually via fine-needle aspiration (FNA). We tested the feasibility of performing gene expression profiling of advanced NSCLCs using amplified RNA from lung FNAs. EXPERIMENTAL DESIGN AND RESULTS: A total of 46 FNAs was tested, of which 18 yielded RNA of sufficient quality for microarray analysis. Expression profiles of these 18 samples were compared with profiles of 17 pairs of tumor and normal lung tissues that had been surgically obtained. Using a variety of unsupervised and supervised analytical approaches, we found that the FNA profiles were highly distinct from the normal samples and similar to the tumor profiles. CONCLUSIONS: We conclude that when RNA amplification is successful, gene expression profiles from NSCLC FNAs can determine malignancy and suggest that with additional refinement and standardization of sample collection and RNA amplification protocols, it will be possible to conduct additional and more detailed molecular analysis of advanced NSCLC using lung FNAs.
Authors: Sedigheh Sharifzadeh; S Mohammad Owji; Abdul Mohammad Pezeshki; Zahra Malek-Hoseini; Perikala Vijayananda Kumar; Sied Mohammad Ali Ghayumi; Abbas Ghaderi Journal: Pathol Oncol Res Date: 2004-12-27 Impact factor: 3.201
Authors: Michelle A Anderson; Dean E Brenner; James M Scheiman; Diane M Simeone; Nalina Singh; Matthew J Sikora; Lili Zhao; Amy N Mertens; James M Rae Journal: J Mol Diagn Date: 2010-08-13 Impact factor: 5.568
Authors: Anna E Szafranska; Martina Doleshal; Hayward S Edmunds; Stuart Gordon; Jutta Luttges; Johanna B Munding; Richard J Barth; Edward J Gutmann; Arief A Suriawinata; J Marc Pipas; Andrea Tannapfel; Murray Korc; Stephan A Hahn; Emmanuel Labourier; Gregory J Tsongalis Journal: Clin Chem Date: 2008-08-21 Impact factor: 8.327